Axol Bioscience Ltd.

Axol Bioscience Ltd.

Axol Bioscience Ltd.

Date Founded



Chesterford Research Park,The Science Village,Suite 3, Little Chesterford,Cambridge, Cambridgeshire CB10 1XL

Type of Company


Employees (Worldwide)

11 - 50


Medical Support Services
Holding Companies

Company Description

Axol Bioscience Ltd. is a biotech company that develops and produces induced pluripotent stem cell-derived clinically relevant cells for use in biomedical research and discovery. Its products include human neural progenitor cells, young frozen human cerebral cortical neurons, plated human cerebral cortical neurons, Alzheimer's disease human neural progenitor cells, reagents, and lipid-based transfection reagents. The firm's products are used in the testing of new drug compounds, as well as in the development of therapies for various diseases, such as Alzheimer's. The company was founded by Yichen Shi and Jonathan Simon Milne and is headquartered in Cambridge, the United Kingdom.

Executives & Employees


Chief Executive Officer & Co-Founder

Chief Marketing Officer

Board of Directors

Co-Founder at Axol Bioscience Ltd.

Chief Operating Officer at Quartix Ltd.

Paths to Axol Bioscience Ltd.
Potential Connections via
Relationship Science
Axol Bioscience Ltd.
Details Hidden

Calculus is a hands-on manager which invests in smaller, unquoted UK companies sector, aiming to identify companies with experienced, capable management teams in attractive market segments and provide finance, advice and support to help them accelerate growth and facilitate profitable exits.The firm seeks to invest in UK companies with sales of £50 million or less, positive EBITDA or a clear route to generating positive EBITDA, the potential to deliver robust, achievable growth and which operate in established sectors of the economy. They focus on smaller management buy-outs, pre-IPO funding, expansion capital and acquisition financing.Calculus seeks to manage risk by investing in a diverse portfolio in oil & gas, media & marketing, support services, retail, financial, transport industrial, applied technology, leisure, and healthcare & life sciences and able to prosper and progress in any economic conditions. They focus on capital growth and capital preservation, aiming to create a sound foundation for growth in their investee companies and have experience in all forms of exits, including trade sales, IPOs, secondary buy-outs or recapitalizations. The firm is managing 16 funds.

Details Hidden
Details Hidden

Founder at Abcam Plc

I'rom Group Co., Ltd. Other Business & Consulting Services | Tokyo, TY

I'rom Group Co., Ltd. engages in the medical support business. It operates through the following business divisions: Advanced Medicinal Treatment Services, Site Management Organization (SMO) Services, Contract Research Organization (CRO) Services and Medical Support Business. The Advanced Medicinal Treatment Services division enages in the development of advanced medical technologies such as regenerative medicine and gene therapy to the practical level has been long awaited. The SMO services division conducts clinical trial, various operations, besides examinations and tests, arise at the medical institution, including data organization and document management. The CRO Services division provides clinical trials of pharmaceuticals or medical devices in the development stage or in post-marketing clinical trials etc. The Medical Support Business division supports the enhancement of convenience and quality of medical care for patients by providing clinic malls. The company was founded on April 9, 1997 and is headquartered in Tokyo, Japan.

Horizon Discovery Group PLC Pharmaceuticals | Cambridge, CA

Horizon Discovery Group Plc is a gene editing company, which engages in the design and engineering of genetically-modified cells. The firm operates through the following business segments: Products, Services, and Leveraged Research and Development. The Products segment sells cell lines and other products. The Services segment offers cell line manufacturing services. The Leveraged Research and Development segment business unit is operated on a portfolio basis. It serves pharmaceutical, biotechnology, and diagnostic companies. The company was founded by Christopher John Torrance, Adam John Collier, and Alberto Bardelli in 2005 and is headquartered in Cambridge, the United Kingdom.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Axol Bioscience Ltd.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Axol Bioscience Ltd.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Axol Bioscience Ltd..